Welcome to the laboratory of Tony Kouzarides
Researching epigenetic modifications and their role in cancer
Welcome to the laboratory of Tony Kouzarides
Researching epigenetic modifications and their role in cancer
Other TK Enterprises:
Professor Sir Tony Kouzarides, FMedSci, FRS
Tony is Professor of Cancer Biology at the University of Cambridge and a Senior Group Leader at the Gurdon Institute. Tony is also the director and co-founder of the new Milner Therapeutics Institute at the University of Cambridge, which has a mission to deliver better therapies by connecting academia with industry.
Professor Tony Kouzarides, FMedSci, FRS
Tony is Professor of Cancer Biology at the University of Cambridge and a Senior Group Leader at the Gurdon Institute. Tony is also the director and co-founder of the new Milner Therapeutics Institute at the University of Cambridge, which has a mission to deliver better therapies by connecting academia with industry.
Selected publications:
• Yankova E et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature, 2021
• Barbieri I and Kouzarides T. Role of RNA modifications in cancer. Nature Reviews Cancer, 2020
• Barbieri I et al. Promoter-bound METTL3 maintains myeloid leukaemia by m6A-dependent translation control. Nature, 2017
The Gurdon Institute
Tennis Court Road
Cambridge, CB2 1QN
United Kingdom
Phone: +44 (0) 1223 334088
Fax: +44 (0) 1223 334089